Navigation Links
Genus Oncology, LLC Announces Orphan Drug Status for GO-203-2c for Treatment of Pancreatic Cancer
Date:3/8/2011

rom a series of first-in-class agents synthesized to target MUC1, an oncoprotein that is overexpressed in many diverse human carcinomas including breast, prostate, lung, colon, pancreatic, and ovarian that have been associated with poor prognosis. Of an estimated 1.4 million cancer cases diagnosed each year in the US, about 900,000 overexpress MUC1, thus making it an attractive target for developing anti-cancer drugs. To date, there are no approved agents that target MUC1.

About Genus Oncology, LLC

Genus Oncology, LLC, is a clinical-stage company formed in 2007 with a mission of discovering, developing, and commercializing new anti-cancer agents that target the MUC1 oncoprotein. Genus' intellectual capital includes more than 20 years of research at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, and a senior management team with significant pharmaceutical industry experience leading successful discovery, development, and commercialization initiatives. For more information, please visit www.genusoncology.com.


'/>"/>
SOURCE Genus Oncology, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genus Oncology, LLC Announces Initiation of Phase I Trial of GO-203-2c in Patients With Solid Tumors
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- The Lupus Foundation of America and Eli Lilly ... results from UNVEIL: understanding the impact of lupus, a ... and the challenges not only for those living with ... which involved over 1,000 people with lupus and lupus ... aspects of life including family, work, finances, treatment experiences ...
(Date:9/16/2014)... -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY ), ... and novel medicines to physicians and patients at accessible ... Baum will be a presenter at the 5 ... York City.  Mr. Baum will discuss the company,s growth ... ophthalmology. The presentation is scheduled for 10:40 a.m. EST on ...
(Date:9/16/2014)... 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), a ... chronic pain, announced today that it has entered into ... in a series of animal studies for levorphanol, the ... release form of levorphanol.  Gavril Pasternak, MD, PhD, of ... Dr. Pasternak said, "Levorphanol is a unique ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
(Date:9/16/2014)... 15, 2014A prospective study that compared patient-reported outcomes ... bone metastases demonstrates that single fraction radiation therapy ... radiation therapy (MFRT) when pain, function and quality ... today at the American Society for Radiation Oncology,s ... that improvements in patients, pain, function and degree ...
(Date:9/16/2014)... Beginning October 1st 2014, Dallas’ Park Cities Pet ... clients who book a recurring visit schedule, and thus receive ... Most recurring visit clients are ones that book ... include clients whose unique work schedules or lifestyles simply require ... basis. The newly introduced 15-minute visit length will only ...
(Date:9/16/2014)... Founded by former Miami Beach mayoral ... political organization fighting to legalize medical marijuana in Florida. ... After Party recently commissioned a shot-for-shot parody video of ... the movie “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called “You’re ... musical parody faithfully recreates the carnival scene made famous ...
(Date:9/16/2014)... September 16, 2014 Florida Hospital announced ... Lightning to extend its partnership and become the Presenting ... as the team’s official health and wellness partner. As ... Hospital will receive a logo and name inclusion on ... two seasons. Florida Hospital has been a sponsorship partner ...
(Date:9/16/2014)... serve of dairy food may reduce the risk of ... foods have not traditionally formed part of the diet. ... by Emeritus Professor Mark Wahlqvist from Monash University,s Department ... Institute, considered the role increased consumption of dairy foods ... longevity. , "In a dominantly Chinese food culture, ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2
... leading neuromodulation company, announced today that beginning January ... by Medicare for incomplete spinal cord injury patients ... Centers for Medicare and Medicaid Services (CMS) establishes ... stimulation (FES) devices including the NESS L300™ Foot ...
... changed in a heartbeat for successful freelance writer Lee Woodruff ... Tonight, was wounded while broadcasting from Iraq. Her experience as ... be the focus of her keynote address at URAC,s Best ... Exhibit, April 1-2, 2009 in Orlando, Fla. , ...
... 11 Rosalind Franklin University,of Medicine and Science ... the first in the nation to provide its students with ... The new,system enables medical educators to present students with individual ... has a proven,accuracy rate of over 90 percent. , ...
... Pain Therapeutics, Inc. (Nasdaq: PTIE ) has received a ... for its New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release ... determined that the NDA is not approved in its present form. ... believes additional non-clinical data will be required to support the approval ...
... 11 Preferred Management Corporation of,Shawnee, OK ... two hospitals near Amarillo, Texas. The hospitals, ... General Hospital in Wellington, are both,federally designated ... are administered by Preferred Management Corporation which ...
... to be ignoring message that methamphetamine is dangerous , , ... that utilizes graphic images actually may not be very ... Project (MMP), created in 2005, featured images that showed ... perceived success of the program had resulted in its ...
Cached Medicine News:Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 2Health News: Medicare to Reimburse for the Bioness L300™ Foot Drop System for Spinal Cord Injury 3Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 2Health News:Best-selling Author Lee Woodruff, Futurist Ian Morrison to Speak at URAC's Best Practices Conference 3Health News:Rosalind Franklin University of Medicine and Science First in Illinois to Equip Students With Computerized Diagnosis System 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 2Health News:Preferred Management Corp. Installs OpusClinicalSuite(R) at 2 Texas Hospitals 3Health News:Study Questions Value of Anti-Meth Campaign 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: